First Time Loading...

Denali Therapeutics Inc
NASDAQ:DNLI

Watchlist Manager
Denali Therapeutics Inc Logo
Denali Therapeutics Inc
NASDAQ:DNLI
Watchlist
Price: 19.71 USD 2.12%
Updated: May 14, 2024

Net Margin
Denali Therapeutics Inc

-43.9%
Current
-168%
Average
-8.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-43.9%
=
Net Income
-145.2m
/
Revenue
330.5m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Denali Therapeutics Inc
NASDAQ:DNLI
2.7B USD
-44%
US
Abbvie Inc
NYSE:ABBV
283.9B USD
9%
US
Amgen Inc
NASDAQ:AMGN
166.1B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
109.9B USD
37%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
107.6B USD
29%
AU
CSL Ltd
ASX:CSL
135.1B AUD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
83.9B USD
2%
US
Moderna Inc
NASDAQ:MRNA
49.2B USD
-116%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-33%
US
Biogen Inc
NASDAQ:BIIB
32.4B USD
12%
KR
Celltrion Inc
KRX:068270
39.6T KRW
25%
Denali Therapeutics Inc
NASDAQ:DNLI
Country US
Market Cap 2.7B USD
Net Margin
-44%
Abbvie Inc
NYSE:ABBV
Country US
Market Cap 283.9B USD
Net Margin
9%
Amgen Inc
NASDAQ:AMGN
Country US
Market Cap 166.1B USD
Net Margin
13%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Country US
Market Cap 109.9B USD
Net Margin
37%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Country US
Market Cap 107.6B USD
Net Margin
29%
CSL Ltd
ASX:CSL
Country AU
Market Cap 135.1B AUD
Net Margin
17%
Gilead Sciences Inc
NASDAQ:GILD
Country US
Market Cap 83.9B USD
Net Margin
2%
Moderna Inc
NASDAQ:MRNA
Country US
Market Cap 49.2B USD
Net Margin
-116%
Seagen Inc
NASDAQ:SGEN
Country US
Market Cap 43.1B USD
Net Margin
-33%
Biogen Inc
NASDAQ:BIIB
Country US
Market Cap 32.4B USD
Net Margin
12%
Celltrion Inc
KRX:068270
Country KR
Market Cap 39.6T KRW
Net Margin
25%

Profitability Report

View the profitability report to see the full profitability analysis for Denali Therapeutics Inc.

Full Profitability Report

See Also

Summary
DNLI intrinsic value, competitors valuation, and company profile.
DCF Valuation
DNLI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DNLI stock valuation using valuation multiples.
Wall Street Estimates
DNLI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DNLI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-43.9%
=
Net Income
-145.2m
/
Revenue
330.5m
What is the Net Margin of Denali Therapeutics Inc?

Based on Denali Therapeutics Inc's most recent financial statements, the company has Net Margin of -43.9%.

ALPHA SPREAD
Join more than 137,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.